Kala Pharmaceuticals, Inc. (0JQ2.L)
USD 4.15
(-14.43%)
USD 4.15
(-14.43%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 55.94 Million USD | -35.56% |
| 2022 | 86.82 Million USD | -37.73% |
| 2021 | 139.42 Million USD | -37.08% |
| 2020 | 221.6 Million USD | 43.6% |
| 2019 | 154.32 Million USD | -30.16% |
| 2018 | 220.96 Million USD | 90.27% |
| 2017 | 116.13 Million USD | 150.67% |
| 2016 | 46.32 Million USD | 448.4% |
| 2015 | 8.44 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 61.6 Million USD | 16.17% |
| 2024 Q1 | 53.03 Million USD | -5.21% |
| 2023 Q4 | 55.94 Million USD | -8.46% |
| 2023 FY | 55.94 Million USD | -35.56% |
| 2023 Q3 | 61.12 Million USD | -8.09% |
| 2023 Q1 | 72.22 Million USD | -16.81% |
| 2023 Q2 | 66.5 Million USD | -7.93% |
| 2022 Q2 | 84.97 Million USD | -23.84% |
| 2022 Q4 | 86.82 Million USD | 1.31% |
| 2022 Q3 | 85.69 Million USD | 0.85% |
| 2022 FY | 86.82 Million USD | -37.73% |
| 2022 Q1 | 111.57 Million USD | -19.98% |
| 2021 Q4 | 139.42 Million USD | -28.06% |
| 2021 Q2 | 215.46 Million USD | -6.25% |
| 2021 FY | 139.42 Million USD | -37.08% |
| 2021 Q3 | 193.81 Million USD | -10.05% |
| 2021 Q1 | 229.82 Million USD | 3.71% |
| 2020 Q3 | 225.09 Million USD | -8.31% |
| 2020 Q2 | 245.51 Million USD | -5.03% |
| 2020 Q1 | 258.52 Million USD | 67.52% |
| 2020 FY | 221.6 Million USD | 43.6% |
| 2020 Q4 | 221.6 Million USD | -1.55% |
| 2019 Q4 | 154.32 Million USD | -4.15% |
| 2019 Q2 | 178.81 Million USD | -9.24% |
| 2019 Q1 | 197.01 Million USD | -10.84% |
| 2019 FY | 154.32 Million USD | -30.16% |
| 2019 Q3 | 161.01 Million USD | -9.96% |
| 2018 FY | 220.96 Million USD | 90.27% |
| 2018 Q4 | 220.96 Million USD | 162.82% |
| 2018 Q1 | 104.98 Million USD | -9.6% |
| 2018 Q2 | 95.59 Million USD | -8.95% |
| 2018 Q3 | 84.07 Million USD | -12.05% |
| 2017 FY | 116.13 Million USD | 150.67% |
| 2017 Q4 | 116.13 Million USD | -6.11% |
| 2017 Q3 | 123.69 Million USD | 332.62% |
| 2017 Q2 | 28.59 Million USD | -23.98% |
| 2017 Q1 | 37.6 Million USD | -18.82% |
| 2016 Q4 | 46.32 Million USD | 0.0% |
| 2016 FY | 46.32 Million USD | 448.4% |
| 2015 FY | 8.44 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| uniQure N.V. | 831.68 Million USD | 93.273% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | 94.03% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | 92.808% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | 66.195% |
| bluebird bio, Inc. | 619.16 Million USD | 90.964% |
| Cara Therapeutics, Inc. | 125.84 Million USD | 55.541% |
| Imunon, Inc. | 21.91 Million USD | -155.264% |
| Editas Medicine, Inc. | 499.15 Million USD | 88.791% |
| IQVIA Holdings Inc. | 26.68 Billion USD | 99.79% |
| Mettler-Toledo International Inc. | 3.35 Billion USD | 98.333% |
| Myriad Genetics, Inc. | 1.19 Billion USD | 95.333% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 98.279% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 96.029% |
| Verastem, Inc. | 149.71 Million USD | 62.63% |
| Walgreens Boots Alliance, Inc. | 81.03 Billion USD | 99.931% |
| Waters Corporation | 4.62 Billion USD | 98.791% |
| Thermo Fisher Scientific Inc. | 98.72 Billion USD | 99.943% |
| Biogen Inc. | 26.84 Billion USD | 99.792% |
| Nektar Therapeutics | 398.03 Million USD | 85.944% |
| Perrigo Company plc | 10.8 Billion USD | 99.482% |
| Dynavax Technologies Corporation | 997.09 Million USD | 94.389% |
| Illumina, Inc. | 10.11 Billion USD | 99.447% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -97.893% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | 92.83% |
| Heron Therapeutics, Inc. | 222.5 Million USD | 74.855% |
| Unity Biotechnology, Inc. | 65.69 Million USD | 14.829% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 99.182% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | 66.157% |
| Evolus, Inc. | 188.99 Million USD | 70.397% |
| Adicet Bio, Inc. | 207.29 Million USD | 73.01% |
| Aclaris Therapeutics, Inc. | 197.4 Million USD | 71.658% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 99.831% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | 72.813% |
| FibroGen, Inc. | 423.52 Million USD | 86.79% |
| Agilent Technologies, Inc. | 10.76 Billion USD | 99.48% |
| OPKO Health, Inc. | 2.01 Billion USD | 97.219% |
| Homology Medicines, Inc. | 47.05 Million USD | -18.896% |
| Geron Corporation | 394.07 Million USD | 85.802% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 98.539% |
| Exelixis, Inc. | 2.94 Billion USD | 98.098% |
| Viking Therapeutics, Inc. | 368.49 Million USD | 84.817% |
| Anavex Life Sciences Corp. | 154.38 Million USD | 63.76% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 95.699% |
| Zoetis Inc. | 14.28 Billion USD | 99.608% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | 90.489% |
| Abeona Therapeutics Inc. | 64 Million USD | 12.582% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 99.754% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 98.129% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 98.286% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | 90.998% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 96.772% |
| Blueprint Medicines Corporation | 1.04 Billion USD | 94.668% |
| Insmed Incorporated | 1.32 Billion USD | 95.793% |
| TG Therapeutics, Inc. | 329.58 Million USD | 83.025% |
| Incyte Corporation | 6.78 Billion USD | 99.175% |
| Emergent BioSolutions Inc. | 1.83 Billion USD | 96.951% |